Liminal Biosciences is a a clinical-stage biopharmaceutical company. Co. has two operating segments: small molecule therapeutics and plasma-derived therapeutics. Small molecule therapeutics segment focused on the discovery and development of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have unmet medical need. Plasma-derived therapeutics segment leverages Co.'s experience in bioseparation technologies used to isolate and purify biopharmaceuticals from human plasma. The LMNL stock yearly return is shown above.
The yearly return on the LMNL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LMNL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|